The Rapid Evolution of Digital Endpoints: Are We Headed in the Right Direction?

"Just over a year ago, we launched our crowdsourced library of digital endpoints, aiming to shine a light on digital measures being used in industry-sponsored trials and galvanize the field around specific measures to speed adoption. During our most recent update of the library, we were struck by the astronomical growth of digital endpoints over such a short time span.
Let the numbers speak for themselves:
The number of unique digital endpoints increased from 34 to 166 in the last 14 months, and the number of sponsors actively collecting digital endpoints in clinical trials of their medical products has increased from 12 to 52.
Last year, 50% of digital endpoints being collected were being used in drug trials — this has increased to 62%, with relatively fewer being used in device and biologic trials.
There has been an increase in the use of digital clinical endpoints during the post-market phase of drug and biologic trials and dwindling in early phase trials, whereas their use in Phase 2 and Phase 3 have held quite steady.
Across investigational products, the positioning of digital endpoints has also changed dramatically: at the library’s initial launch, roughly 40% of digital endpoints were exploratory; now, they only account for just over 10% — indicating increasing confidence in their use..." Lire la suite